Abstracts Archive - Page 2114 of 2607 - ACR Meeting Abstracts

Abstract Number: 1785 • 2014 ACR/ARHP Annual Meeting
Survival of Microscopic Polyangiitis (MPA) Patients with and without Pulmonary Fibrosis (PF)
Lina María Saldarriaga Rivera, Natllely Ruiz and Luis F. Flores-Suarez, Primary Systemic Vasculitides Clinic, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico
Background/Purpose:Pulmonary fibrosis (PF) occurs in up to 30% of patients with microscopic polyangiitis (MPA). Data suggest PF implies a higher mortality. We examined the survival…
Abstract Number: 1803 • 2014 ACR/ARHP Annual Meeting
Knee Osteoarthritis and All-Cause Mortality: The Wuchuan Osteoarthritis Study
Qiang Liu¹, Xu Tang Sr.², Jingbo Niu³, Xu Wu⁴, Yan Ke⁵, Jian Huang⁶, Rujun Li⁵, Hu Li⁵, Xin Zhi⁵, Kai Wang⁵, Zhengming Cao¹ and Jianhao Lin², ¹Arthritis Institute, People’s Hospital, Peking University, Beijing, China, ²Peking University Health Science Center, Beijing, China, ³Clinical Epidemiology Research and Training Unit, Boston University, Boston, MA, ⁴Peking University People's Hospital Arthritis Clinic & Research Center, Peking University Health Science Center, Beijing, China, ⁵Peking University People’s Hospital, Beijing, China, ⁶Orthopeadics, The Second Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China
Background/Purpose Several studies published recently found that knee osteoarthritis (OA) is associated with an increased mortality in Caucasians. While prevalence of knee OA is higher…
Abstract Number: 1802 • 2014 ACR/ARHP Annual Meeting
Are Outcomes after Total Knee Arthroplasty Worsening over Time? a Time-Trends Study of Activity Limitation and Pain Outcomes
Jasvinder A. Singh¹ and David Lewallen², ¹University of Alabama and VA Medical Center, Birmingham, AL, ²Orthopedics, Mayo Clinic college of medicine, Rochester, MN
Background/Purpose: To examine whether function and pain outcomes of patients undergoing primary total knee arthroplasty (TKA) are changing over time.Methods: The Mayo Clinic Total Joint…
Abstract Number: 1801 • 2014 ACR/ARHP Annual Meeting
The Association of Knee Shape with Sex: The Osteoarthritis Initiative
Barton L. Wise¹, Lisa Kritikos², Felix Liu³, Neeta Parimi³, John A. Lynch⁴, Yuqing Zhang⁵ and Nancy E. Lane¹, ¹Internal Medicine, Center for Musculoskeletal Health, UC Davis School of Medicine, Sacramento, CA, ²Center for Musculoskeletal Health, UC Davis School of Medicine, Sacramento, CA, ³University of California at San Francisco, San Francisco, CA, ⁴Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, CA, ⁵Boston University School of Medicine, Boston, MA
Background/Purpose: Incidence of knee osteoarthritis (OA) is much higher in women than in men. Previous studies have shown that bone shape is a risk factor…
Abstract Number: 1799 • 2014 ACR/ARHP Annual Meeting
Elevated Indoleamine-2,3-Dioxygenase (IDO) Activity and Kynurinene-3-Monooxygenase (KMO) Expression in Interferon Positive Primary Sjogrens Syndrome Patients Is Associated with Increased CD25^hiFoxP3⁺regulatory Tcells: A Skew Towards Neurotoxicity or an Attempt to Rescue?
Naomi I Maria¹, Cornelia G. van Helden-Meeuwsen¹, Zana Brkic¹, Sandra M.J. Paulissen^1,2, Virgil A. Dalm¹, Paul L. van Daele¹, P. Martin van Hagen¹, Sinead M. Gibney^1,3, Andrew Harkin³, Hemmo A. Drexhage¹, Erik Lubberts^1,2 and Marjan A. Versnel¹, ¹Erasmus Medical Center, Immunology, Rotterdam, Netherlands, ²Erasmus Medical Center, Rheumatology, Rotterdam, Netherlands, ³Trinity College Institute of Neuroscience, Neuropsychopharmacology, Dublin, Ireland
Background/Purpose: A role for indoleamine-2,3-dioxygenase (IDO) in suppression of effector T-cell function and promotion of regulatory T-cell (Treg) differentiation has been described. IDO - the…
Abstract Number: 1798 • 2014 ACR/ARHP Annual Meeting
Interaction Between Innate Immunity and Anti-Ro52 Antibodies is Critical for the Induction of Sjogren’s Syndrome-like Disease in Mice
Paulina Kaplonek¹, Barbara Szczerba², Nina Wolska¹, Paulina Rybakowska¹, Arkadiusz Klopocki¹, Paromita Dey³, Astrid Rasmussen⁴, Kimberly Hefner⁵, Stephen Young⁶, Donald U. Stone⁷, David M. Lewis⁶, Lida Radfar⁸, R. Hal Scofield⁴, Kathy Moser Sivils⁹, Harini Bagavant⁹ and Umesh Deshmukh⁹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Virginia, Charlottesville, VA, ³Department of Medicine, University of Virginia, Charlottesville, VA, ⁴Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Hefner Eye Care and Optical Center, Oklahoma City, OK, ⁶College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁷Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁸College of Dentristry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose . Autoantibodies reactive with Ro52 are present in almost 70% of Sjögren’s syndrome (SS) patients. This study was undertaken to investigate the role of…
Abstract Number: 1797 • 2014 ACR/ARHP Annual Meeting
One-Year Survival of Adults with Systemic Sclerosis Following Lung Transplantation: A Nationwide Cohort Study
Elana J. Bernstein¹, Eric R. Peterson², Joan M. Bathon² and David J. Lederer², ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Medicine, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Lung transplantation is a potentially life-saving treatment for patients with systemic sclerosis (SSc) who have developed end-stage lung disease due to interstitial lung disease…
Abstract Number: 1796 • 2014 ACR/ARHP Annual Meeting
Autotaxin Is Highly Expressed in Systemic Sclerosis (SSc) Skin, Mediates Dermal Fibrosis Via IL-6, and Is a Target for SSc Therapy
Flavia V. Castelino^1,2, Leaya M. George³, Gretchen Bain⁴, Lance Goulet⁵, Robert Lafyatis⁶ and Andrew M. Tager^3,7, ¹Rheumatology, Massachusetts General Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Pulmonary Unit, Massachusetts General Hospital, Boston, MA, ⁴Biology, PharmAkea Pharmaceuticals, San Diego, CA, ⁵PharmAkea Pharmaceuticals, San Diego, CA, ⁶Rheumatology, Boston University School of Medicine, Boston, MA, ⁷Massachusetts General Hospital, Boston, MA
Background/Purpose Autotaxin (ATX) is an enzyme present in biological fluids that is responsible for the production of the lipid mediator, lysophosphatidic acid (LPA). We previously…
Abstract Number: 1795 • 2014 ACR/ARHP Annual Meeting
Denosumab Restores Cortical Bone Loss at the Distal Radius Associated with Aging and Reduces Wrist Fracture Risk: Analyses from the Cross-over Group in the Extension of the Denosumab Pivotal Fracture Trial
JP Bilezikian¹, CL Benhamou², CJF Lin³, JP Brown⁴, NS Daizadeh³, PR Ebeling⁵, A Fahrleitner-Pammer⁶, E Franek⁷, N Gilchrist⁸, PD Miller⁹, JA Simon¹⁰, I Valter¹¹, CAF Zerbini¹² and C Libanati³, ¹College of Physicians and Surgeons, Columbia University, New York, NY, ²CHR d'Orléans, Orléans, France, ³Amgen Inc., Thousand Oaks, CA, ⁴CHU de Québec Research Centre and Laval University, Quebec City, QC, Canada, ⁵Monash University, Clayton, Australia, ⁶Medical University, Graz, Austria, ⁷Medical Research Center, Polish Academy of Sciences, Warsaw, Poland, ⁸The Princess Margaret Hospital, Christchurch, New Zealand, ⁹Colorado Center for Bone Research, Lakewood, CO, ¹⁰George Washington University, Washington, DC, ¹¹Center for Clinical and Basic Research, Tallinn, Estonia, ¹²Centro Paulista de Investigação Clinica, São Paulo, Brazil
Background/Purpose: Cortical bone loss is a major determinant of increased fracture risk. Denosumab (DMAb) has been shown to increase BMD at sites of cortical bone,…
Abstract Number: 1794 • 2014 ACR/ARHP Annual Meeting
The Sting Pathway Regulates Bone Remodeling in a Model of Autoimmune Disease
Rebecca Baum¹, Jason M. Organ², David B. Burr³, Ann Marshak-Rothstein⁴, Katherine A. Fitzgerald⁵ and Ellen M. Gravallese⁶, ¹Cell Biology, University of Massachusetts Medical School, Worcester, MA, ²Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, ³Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, Indiana, ⁴Department of Medicine, Division of Rheumatology, University of Massachusetts Medical School, Worcester, MA, ⁵Department of Medicine, Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA, ⁶Department of Medicine, Division of Rheumatology, UMass Memorial Medical Center, Worcester, MA
Background/Purpose: Cytosolic DNA sensors detect viral and bacterial DNA, inducing inflammatory cytokines and type I IFNs via the adaptor stimulator of interferon genes (STING) to…
Abstract Number: 1793 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of IFN-Alpha in Induction and Maintenance of Remission in Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA). Single Center Observational Study
Benjamin Seeliger¹, Martin Foerster¹, Anne Moeser¹, Janett Happe¹, Claus Kroegel¹ and Thomas Neumann², ¹Jena University Hospital, Internal Medicine I, Jena, Germany, ²Jena University Hospital, Internal Medicine III, Jena, Germany
Background/Purpose: To evaluate the efficiency and safety of IFN-alpha in induction and maintenance of remission in patients with EGPA and to describe its effects on…
Abstract Number: 1792 • 2014 ACR/ARHP Annual Meeting
Clinical-Biological and Pathological Spectrum and Outcome of IgA Vasculitis in Adults: A French Study
Alexandra Audemard¹, Evangeline Pillebout², Patrice Cacoub³, Noémie Jourde-Chiche Sr.⁴, Zahir Amoura⁵, Noemie Le Gouellec⁶, Francois Maurier⁷, Boris Bienvenu⁸, Geoffrey Urbanski⁹, Sébastien Sanges¹⁰, Aurélie Hummel¹¹, Alban Deroux¹², Loic Raffray¹³, Luc Mouthon¹⁴, Loïc Guillevin for the French Vasculitis Study Group¹⁴, Eric Thervet¹⁵ and Benjamin Terrier¹⁶, ¹Internal Medicine, Centre Hospitalier Universitaire de Caen, Caen, France, ²Nephrology, Saint Louis, Paris, France, ³Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, ⁴Nephrology, CHU, Marseille, France, ⁵Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ⁶Internal Medicine, Lille, France, ⁷HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ⁸Médecine interne, CHU Côte de Nacre, CAEN, France, ⁹Internal Medicine, CHRU, Lille, France, ¹⁰Service de médecine interne, Centre National de Référence de la Sclérodermie Systémique, Hôpital Claude Huriez, CHRU Lille, Lille, France, ¹¹Nephrology, Necker Hospital, Paris, France, ¹²Internal Medicine, CHU Grenoble, Grenoble, France, ¹³INTERNAL MEDICINE, bordeaux, France, ¹⁴National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹⁵Nephrology, Hopital Européen Georges Pompidou, APHP, PARIS, France, ¹⁶National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France
Background/Purpose IgA vasculitis is an immune-complex small-vessel vasculitis that mainly affects children and, more rarely, adults, in whom it seems to be more severe, because…
Abstract Number: 1804 • 2014 ACR/ARHP Annual Meeting
Increased Mortality in Ankylosing Spondylitis – Results from a National Population Based Study
Sofia Exarchou¹, Elisabeth Lie², Johan Askling³, Helena Forsblad-d'Elia², Carl Turesson¹, Lars Erik Kristensen⁴ and Lennart T. Jacobsson², ¹Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ³Clinical Epidemiology Unit, Rheumatology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Section of Rheumatology, Department of Clinical Sciences, Lund University, Malmö, Sweden
Background/Purpose: Ankylosing spondylitis (AS) is characterized both by inflammation of the axial skeleton and systemic inflammation, and may also involve joints, entheses and other organs.…
Abstract Number: 1800 • 2014 ACR/ARHP Annual Meeting
Objectively Measured Sedentary Behavior Is a Distinct Risk Factor from Low Moderate-to-Vigorous Activity in Predicting Subsequent Frailty: Evidence from Osteoarthritis Initiative
Jing Song¹, Lee A. Lindquist¹, Rowland W. Chang¹, Pamela A. Semanik², Linda S. Ehrlich-Jones³, Jungwha Lee⁴, Min-Woong Sohn¹ and Dorothy D. Dunlop¹, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Rush University Medical Center, Chicago, IL, ³Rehabilitation Institute of Chicago, Chicago, IL, ⁴Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Physical frailty represents a state of high vulnerability for adverse health outcomes including disability and mortality. Physical activity interventions to improve health have largely…
Abstract Number: 1777 • 2014 ACR/ARHP Annual Meeting
Staphylococcus Aureus Nasal Carriage and Relapses, Bvas, ANCA-Positivity and Cotrimoxazole Use in ANCA-Associated Vasculitis
Boun Kim Tan¹, Yoann Crabol¹, Jason Tasse^2,3, Frederic Laurent^2,3, Xavier Puechal^4,5, Christine Vinter⁶ and Loïc Guillevin^1,5, ¹Internal Medicine, Hôpital Cochin, University Paris V Descartes, Paris, France, ²Laboratoire de Bactériologie de l'hôpital de la Croix-Rousse, National Reference Centre for Staphylococci, Lyon, France, ³INSERM U1111, CNRS UMR5308, International Centre for Research in Infectious Diseases, Lyon, France, ⁴Internal Medicine, Hôpital Cochin, Paris, France, ⁵French Vasculitis Study Group (FVSG), Paris, France, ⁶Internal Medecine, Hôpital Cochin, Paris, France
Background/Purpose Staphylococcus aureus (SA) nasal carriage has been reported to be more frequent and associated with persistent ANCA-positivity and relapse in patients with granulomatosis with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].